GSK2251052
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
ABSTRACT The emergence of multidrug-resistant (MDR) Gram-negative bacilli is a major concern in the treatment of nosocomial…
ABSTRACT GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in…
ABSTRACT GSK2251052, a novel leucyl-tRNA synthetase (LeuRS) inhibitor, was in development for the treatment of infections caused…
ABSTRACT The plasma and intrapulmonary pharmacokinetics (PK) of intravenous (i.v.) GSK2251052, a novel boron-containing…
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing…
ABSTRACT We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916…
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing…
10 Running Title: Pulmonary and Plasma PK of GSK2251052 11 12 13 # Corresponding author: Parul Patel, Pharm.D. 14 GlaxoSmithKline…
Background: GSK2251052 (formerly AN3365), a novel boron-containing leucyl-tRNA synthetase inhibitor with in vitro activity…